CD274 and neoplasm: Previous work has shown PD-L1 staining to be variable between primary tumour sites and histologies with significant variation within single histologies or even intratumoural variation.9–11 Our findings here demonstrate a significant proportion of MPM patients express PD-L1 and may therefore potentially benefit from PD-1 inhibition.